Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group

作者：Thomas Theodor Werner Seufferlein, Waldemar H. Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander Otto König, Michael B. Ghadimi, Eike Gallmeier, Detlef Klaus Bartsch, Manfred Paul Lutz, Ralf Metzger, Kai Wille, B. Gerdes, Carl Christoph Schimanski, Florian Graupe, Volker Kunzmann, Ingo Klein, Michael Geißler, Ludger Staib, Daniel F. Waldschmidt, Christiane J. Bruns, Uwe A. Wittel, Stefan Fichtner‐Feigl, S Daum, Axel Hinke, L. Blomé, Andrea Tannapfel, Alexander Kleger, Adam Berger, Angelika M. R. Kestler, J.S. Schuhbaur, Lukas Perkhofer, Margaret A. Tempero, Anke Reinacher‐Schick, Thomas Jens Ettrich · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.09.161 · 被引用次数：168 · 研究领域：Pancreatic and Hepatic Oncology Research、Cancer, Stress, Anesthesia, and Immune Response、Cholangiocarcinoma and Gallbladder Cancer Studies